Difference between revisions of "Team:TecMonterrey GDL/Constructs"
| Line 142: | Line 142: | ||
<h4 align="left"> Composite part Plan A: </h4> | <h4 align="left"> Composite part Plan A: </h4> | ||
<h4 align="right"> For L. rhamnosus <h4> | <h4 align="right"> For L. rhamnosus <h4> | ||
| + | <h1></h1> | ||
<img src="https://static.igem.org/mediawiki/2018/4/4e/T--TecMonterrey_GDL--Construct23.png" align="right"> | <img src="https://static.igem.org/mediawiki/2018/4/4e/T--TecMonterrey_GDL--Construct23.png" align="right"> | ||
<span> This is the same “Plan A” for E. coli but adapted to Lactobacillus rhamnosus GG, since it is a natural probiotic organism. Plan A which consists of producing the soluble form gp130 attached to novel signal peptides for secretion to the media, this proteins will form a dimer with gp80 found in the gut, which will then attach to IL-6 and form a stable trimer capable of blocking interleukin inflammatory signalization. The construct is codon optimized for L. rhamnosus GG, it has promoters, RBS and terminators that have been used before for L. rhamnosus. It also contains two restriction sites, between the iGEM prefix and suffix, to ligate the Lactobacillus ORI site. | <span> This is the same “Plan A” for E. coli but adapted to Lactobacillus rhamnosus GG, since it is a natural probiotic organism. Plan A which consists of producing the soluble form gp130 attached to novel signal peptides for secretion to the media, this proteins will form a dimer with gp80 found in the gut, which will then attach to IL-6 and form a stable trimer capable of blocking interleukin inflammatory signalization. The construct is codon optimized for L. rhamnosus GG, it has promoters, RBS and terminators that have been used before for L. rhamnosus. It also contains two restriction sites, between the iGEM prefix and suffix, to ligate the Lactobacillus ORI site. | ||
| + | </span> | ||
| + | <img src="https://static.igem.org/mediawiki/2018/b/bf/T--TecMonterrey_GDL--ConstructEColi.png" align="left" > | ||
| + | <span> Soluble forms of both receptor IL-6 subunits are present in human blood, in general, soluble receptors for several cytokines have been detected in different body fluids, these are believed to help modulate cytokine response by binding the ligand and thereby reducing its bioavailability. Since the combination of soluble gp130 and gp80 can act as an antagonist vs the cells with membrane-bound receptor (IL-6R) [1] , the Plan A strategy was developed as a first approach towards developing our psychobiotic. | ||
</span> | </span> | ||
</div> | </div> | ||
<div> | <div> | ||
Revision as of 22:55, 5 October 2018
Construct Design
Composite part Plan A:
This construct is optimized for E.coli BL21, it constitutes our “Plan A” for our psychobiotic, which consists of producing the soluble form gp130 attached to novel signal peptides, which will allow the secretion of the sgp130 to the extracellular media. In order for our construct to work the IL-6 will bind to its receptor also known as gp80, these dimer will then bind to the produced soluble sgp130 which will form a highly stable trimer that sequesters IL-6, effectively inhibiting IL-6 trans-signaling, the inflammatory signalization.
Both the IL-6 and the soluble form of the IL-6 receptor are present in the human body specifically in the gut, where our construct will work. In general, soluble receptors for several cytokines have been detected in different body fluids, these are believed to help modulate cytokine response by binding the ligand and thereby reducing its bioavailability. Since the of soluble gp130 can act as an antagonist vs the cells with membrane-bound receptor (IL-6R) [1] , the Plan A strategy was developed as a first approach towards developing our psychobiotic.
The system contains an inducible promoter that will be regulated by nitrosative stress. When this stress is present, the transcription of the soluble form of gp130 will be initiated. Additionally, a inducible pBad promoter will be activated with arabinose in order to control the production of NsrR, the protein that blocks the transcription of the Pyear promoter, these will be a form to control the amount of nitrosative stress needed for the Pyear activation. Reporter fluorescent proteins iLOV and M-Cherry will help us corroborate expression of both systems. iLOV will be attached to the Pbad-nsrR system and M-Cherry to the PyeaR-sgp130 system. The sgp30 have a His-Tag (6 histidines) attached to it for purification.
References: [1] Müller-Newen, G., Küster, A., Hemmann, U., Keul,R., Horsten, U., Martens, A., Graeve, L., Wijdenes, J., Heinrich, P. (1998) Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses. The Journal American of Association Immunology. ISSN: 1550-6606. [2] Han,S., Machhi, S., Berge,H., Xi, G., Linke, T., and Schoner, R. (2017). Novel signal peptides improve the secretion of recombinant Staphylococcus aureus Alpha toxinH35L in Escherichia coli. AMB Express. Doi: https://doi.org/10.1186/s13568-017-0394-1
Composite part Plan B (E. coli BL21):
This construct is optimized for E.coli BL21, it constitutes our “Plan B” for our psychobiotic, which consists of producing a soluble, mutated, gp80 attached to novel signal peptides for secretion to the media from E. coli BL21. The production of the mutated alpha chain receptor for IL-6 (gp80) will act as an antagonist protein, due to mutations, it will associate with IL-6 forming the IL-6-alphaReceptorgp80 complex but it will not bind with human gp130, thus inhibiting the formation of IL-6-alphaReceptorgp80-gp130 complex which leads to inflammation pathways [1].
The system is first regulated by a Pbad promoter, which allows to induce expression with L-arabinose of the nsrR repressor protein (of PyeaR promoter) and then regulate the expression of mutated gp80 with the PyeaR promoter, after it senses nitrosative stress. Reporter fluorescent proteins iLOV and M-Cherry will help us corroborate expression of both promoter systems. iLOV will be attached to the Pbad-nsrR system and M-Cherry to the PyeaR-Mutatedgp80 system. The mutated gp80 has a His-Tag (6 histidines) attached to it for purification purposes. It is also attached to a signal peptide for excretion into the media.
References: [1] Müller-Newen, G., Küster, A., Hemmann, U., Keul,R., Horsten, U., Martens, A., Graeve, L., Wijdenes, J., Heinrich, P. (1998) Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses. The Journal American of Association Immunology. ISSN: 1550-6606. [2] Han,S., Machhi, S., Berge,H., Xi, G., Linke, T., and Schoner, R. (2017). Novel signal peptides improve the secretion of recombinant Staphylococcus aureus Alpha toxinH35L in Escherichia coli. AMB Express. Doi: https://doi.org/10.1186/s13568-017-0394-1
Composite part Plan A:
For L. rhamnosus
This is the same “Plan A” for E. coli but adapted to Lactobacillus rhamnosus GG, since it is a natural probiotic organism. Plan A which consists of producing the soluble form gp130 attached to novel signal peptides for secretion to the media, this proteins will form a dimer with gp80 found in the gut, which will then attach to IL-6 and form a stable trimer capable of blocking interleukin inflammatory signalization. The construct is codon optimized for L. rhamnosus GG, it has promoters, RBS and terminators that have been used before for L. rhamnosus. It also contains two restriction sites, between the iGEM prefix and suffix, to ligate the Lactobacillus ORI site.
Soluble forms of both receptor IL-6 subunits are present in human blood, in general, soluble receptors for several cytokines have been detected in different body fluids, these are believed to help modulate cytokine response by binding the ligand and thereby reducing its bioavailability. Since the combination of soluble gp130 and gp80 can act as an antagonist vs the cells with membrane-bound receptor (IL-6R) [1] , the Plan A strategy was developed as a first approach towards developing our psychobiotic.
This is the same “Plan A” for E. coli but adapted to Lactobacillus rhamnosus GG, since it is a natural probiotic organism. Plan A which consists of producing the soluble form gp130 attached to novel signal peptides for secretion to the media, this proteins will form a dimer with gp80 found in the gut, which will then attach to IL-6 and form a stable trimer capable of blocking interleukin inflammatory signalization. The construct is codon optimized for L. rhamnosus GG, it has promoters, RBS and terminators that have been used before for L. rhamnosus. It also contains two restriction sites, between the iGEM prefix and suffix, to ligate the Lactobacillus ORI site.
Soluble forms of both receptor IL-6 subunits are present in human blood, in general, soluble receptors for several cytokines have been detected in different body fluids, these are believed to help modulate cytokine response by binding the ligand and thereby reducing its bioavailability. Since the combination of soluble gp130 and gp80 can act as an antagonist vs the cells with membrane-bound receptor (IL-6R) [1] , the Plan A strategy was developed as a first approach towards developing our psychobiotic.